RecallDepth
Class III Terminated

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

This recall has been terminated (originally issued May 14, 2014).

Company
Merck & Co Inc
Recall Initiated
January 13, 2014
Posted
May 14, 2014
Recall Number
D-1310-2014
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
20,259 cartons
Firm Location
Whitehouse Station, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

Distribution

Nationwide and Puerto Rico

Lot / Code Info

a) Liptruzet 10/20mg 30 count, 346353, 346354, Exp. 06/14; 351809, Exp. 07/14, 360530, Exp. 12/14. b) Liptruzet 10/20mg, 90 count, 346387, Exp. 06/14; 353185, Exp.12/14.

Other recent Class III Drug recalls